Michael Gilman
Director/Board Member bij SCHOLAR ROCK HOLDING CORPORATION
Vermogen: 665 272 $ op 31-03-2024
Profiel
Michael Gilman was the founder of Stromedix, Inc. (founded in 2006) where he served as the Chief Executive Officer in 2012.
He was also the founder of X4 Pharmaceuticals, Inc. (founded in 2014) where he held the position of Director.
Additionally, he is the founder of Padlock Therapeutics, Inc. (founded in 2014) and currently serves as the President, Director, and Secretary.
Dr. Gilman's current job(s) include being the Chief Executive Officer & Director at Arrakis Therapeutics, Inc. since 2016, a Director at Scholar Rock, Inc. since 2013, a Director at Obsidian Therapeutics, Inc. since 2016, an Independent Director at Scholar Rock Holding Corp.
since 2013, and a Scientific Advisor at FutuRx Ltd.His former job positions include being a Director at EPIX Pharmaceuticals, Inc. and Via Science, Inc. He was also the Chief Scientific Officer & Executive VP at ARIAD Pharmaceuticals, Inc. from 1994 to 1999.
In addition, he served as the Senior Vice President-Early-Stage Pipeline at Biogen, Inc. from 2012 to 2013 and as the Executive Vice President-Research at Biogen, Inc. from 1999 to 2005.
Dr. Gilman obtained his undergraduate degree from Massachusetts Institute of Technology in 1976 and his doctorate degree from the University of California, Berkeley in 1983.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 21-06-2023 | 37 459 ( 0.05% ) | 665 272 $ | 31-03-2024 |
Actieve functies van Michael Gilman
| Bedrijven | Functie | Begin |
|---|---|---|
| SCHOLAR ROCK HOLDING CORPORATION | Director/Board Member | 01-11-2013 |
Padlock Therapeutics, Inc.
 Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Founder | 01-01-2014 |
Scholar Rock, Inc.
 Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Director/Board Member | 01-11-2013 |
Arrakis Therapeutics, Inc.
 Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Chief Executive Officer | 01-10-2016 |
Obsidian Therapeutics, Inc.
 Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Director/Board Member | 01-10-2016 |
FutuRx Ltd.
 FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Consultant / Advisor | - |
Eerdere bekende functies van Michael Gilman
| Bedrijven | Functie | Einde |
|---|---|---|
X4 Pharmaceuticals, Inc. /Old/
 X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | Founder | 01-03-2019 |
| BIOGEN INC. | Corporate Officer/Principal | 01-06-2013 |
Stromedix, Inc.
 Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Founder | 01-03-2012 |
| ░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | - |
| ░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░ ░░░░░░░░░░░░ ░░░░░░░ | ░░░░░░░░░░ |
Opleiding van Michael Gilman
| Massachusetts Institute of Technology | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| BIOGEN INC. | Health Technology |
| SCHOLAR ROCK HOLDING CORPORATION | Health Technology |
| Bedrijven in privébezit | 10 |
|---|---|
ARIAD Pharmaceuticals, Inc.
 ARIAD Pharmaceuticals, Inc. BiotechnologyHealth Technology ARIAD Pharmaceuticals, Inc. operates as an oncology company, which engages in the discovery, development, and commercialization of small-molecule drugs for the treatment of cancer. The company was founded by Harvey J. Berger and James E. Rothman on January 8, 1992 and is headquartered in Cambridge, MA. | Health Technology |
EPIX Pharmaceuticals, Inc.
 EPIX Pharmaceuticals, Inc. Medical SpecialtiesHealth Technology EPIX Pharmaceuticals, Inc. used to develop targeted contrast agents both to improve the capability and expand the use of magnetic resonance imaging (MRI) as a tool for diagnosing human disease. The company was founded in 1988 and was headquartered in Lexington, MA. | Health Technology |
Stromedix, Inc.
Stromedix, Inc. Pharmaceuticals: MajorHealth Technology Stromedix, Inc. develops novel drugs to treat fibrosis and fibrotic organ failure. The company was founded by Michael Gilman in 2006 and is headquartered in Cambridge, MA. | Health Technology |
X4 Pharmaceuticals, Inc. /Old/
X4 Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology X4 Pharmaceuticals, Inc. develops novel therapeutics designed to improve immune cell trafficking to treat cancer and rare diseases. It offers X4P-001-RD, X4P-001-IO, and X4P-002. The company was founded by Paula Ragan, Alan Walts, Michael Gilman, Henri Termeer, Keith Flaherty, Renato Skerlj, and Richard Peters in July 2014 and is headquartered in Cambridge, MA. | Health Technology |
Via Science, Inc.
 Via Science, Inc. Packaged SoftwareTechnology Services Via Science, Inc. operates as a patented, automated analytics platform to solve high-value complex problems. It offers Trusted Analytics Chain? (TAC?), a platform which offers privacy protection, virtual pooling, and regulatory compliance. The company was founded by Colin Gounden, Kate Ravanis, Jeremy Taylor, Iya Khalil and Colin Hill in 2000 and is headquartered in Somerville, MA. | Technology Services |
Padlock Therapeutics, Inc.
Padlock Therapeutics, Inc. BiotechnologyHealth Technology Padlock Therapeutics, Inc. develops medicines targeting protein-arginine deiminases. It develops drugs that block the protein-arginine deiminase (PAD) enzymes. The firm leverages the breakthrough science on the role of protein citrullination in disease to develop drugs targeting protein-arginine deiminase (PAD) enzymes. The company was founded by Paul Thompson, Kerri Mowen, Todd A. Huffman and Michael Gilman in January 2014 and is headquartered in Cambridge, MA. | Health Technology |
Scholar Rock, Inc.
Scholar Rock, Inc. BiotechnologyHealth Technology Scholar Rock, Inc. operates as a biotechnology company. It focuses on discovering and developing a novel class of biologic therapies that target supracellular activation of growth factors in the disease microenvironment. The company was founded by Timothy Springer and Leonard Zon and is headquartered in Cambridge, MA. | Health Technology |
FutuRx Ltd.
FutuRx Ltd. Investment ManagersFinance FutuRx Ltd (FutuRx ) is a venture capital firm founded in 2014. The firm is headquartered in Ness Ziona. | Finance |
Obsidian Therapeutics, Inc.
Obsidian Therapeutics, Inc. BiotechnologyHealth Technology Obsidian Therapeutics, Inc. develops cell and gene therapeutics that employ precise exogenous control of transgenes for improved safety and efficacy. The company was founded in 2016 and is headquartered in Cambridge, MA. | Health Technology |
Arrakis Therapeutics, Inc.
Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Health Technology |
